CAS 303-49-1|Clomipramine

Introduction:Basic information about CAS 303-49-1|Clomipramine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Common NameClomipramine
CAS Number303-49-1Molecular Weight314.852
Density1.1±0.1 g/cm3Boiling Point434.2±45.0 °C at 760 mmHg
Molecular FormulaC19H23ClN2Melting Point/
MSDS/Flash Point216.4±28.7 °C

Names

Nameclomipramine
SynonymMore Synonyms

Clomipramine BiologicalActivity

DescriptionClomipramine (Chlorimipramine) is a potent 5-HT reuptake blocker with the IC50 value of 1.5 nM. Clomipramine is a tricyclic antidepressant that can be used for the research of depression and obsessive compulsive disorder (OCD)[1].
Related CatalogResearch Areas >>Neurological DiseaseSignaling Pathways >>Neuronal Signaling >>Serotonin Transporter
In VitroClomipramine can inhibit reuptake of both noradrenaline and 5-HT, although Clomipramine inhibits 5-HT reuptake more strongly than it inhibits noradrenaline reuptake[1]. The antidepressant Clomipramine inhibits both venom AChE as well as human serum BChE in a concentration-dependent manner but has no effect on AChE in the rat brain striatum[2]. Clomipramine interferes with the autophagic flux and severely compromises the viability of tumorigenic cells upon cytotoxic stress[3]. Clomipramine reduces autophagy in neuronal primary cultures. Clomipramine (1 and 5 µM) negatively regulates neuronal autophagic pathway in primary cultured cells[3]. Western Blot Analysis[3] Cell Line: Primary cortical neurons Concentration: 1 and 5 µM Incubation Time: 12, 24 and 48 hours Result: Enhanced the LC3-I conversion to LC3-II in a concentration-dependent manner at all analyzed time points.
In VivoClomipramine (5-20 mg/kg; i.p) elicits significant hyperglycemia in mice. Clomipramine induces hyperglycemia in mice by blocking the 5-HT2B and/or 5-HT2C receptors, which results in facilitation of adrenaline release. In mice, Clomipramine reduces immobility in the forced swimming test, which is the behavioral model for antidepressants. Clomipramine also inhibits the OCD animal model, marble burying behavior in mice[1]. Clomipramine (20 mg/kg) decreases autophagic flux in murine tissues[3]. Animal Model: C57BL/6 J mice (6 weeks of age and 22 to 25 g)[3] Dosage: 20 mg/kg Administration: Treated intraperitoneally for 21 days Result: Both LC3-II and p62 were significantly increased in the liver of Clomipramine treated mice compared to vehicle treated ones.
References

[1]. Yumi Sugimoto, et al. The tricyclic antidepressant Clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9.

[2]. Mushtaq Ahmed, et al. Comparative study of the inhibitory effect of antidepressants on cholinesterase activity in Bungarus sindanus (krait) venom, human serum and rat striatum. J Enzyme Inhib Med Chem. 2008 Dec;23(6):912-7.

[3]. Federica Cavaliere,The tricyclic antidepressant Clomipramine inhibits neuronal autophagic flux. Sci Rep. 2019 Mar 19;9(1):4881.

Chemical & Physical Properties

Density1.1±0.1 g/cm3
Boiling Point434.2±45.0 °C at 760 mmHg
Molecular FormulaC19H23ClN2
Molecular Weight314.852
Flash Point216.4±28.7 °C
Exact Mass314.154968
PSA6.48000
LogP5.39
Vapour Pressure0.0±1.0 mmHg at 25°C
Index of Refraction1.582
InChIKeyGDLIGKIOYRNHDA-UHFFFAOYSA-N
SMILESCN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
Water SolubilityH2O: 25 mg/mL

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
HN9050000
CHEMICAL NAME :
5H-Dibenz(b,f)azepine, 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-
CAS REGISTRY NUMBER :
303-49-1
BEILSTEIN REFERENCE NO. :
1323477
LAST UPDATED :
199612
DATA ITEMS CITED :
16
MOLECULAR FORMULA :
C19-H23-Cl-N2
MOLECULAR WEIGHT :
314.89
WISWESSER LINE NOTATION :
T C676 BN&T&J B3N1&1 EG

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
357 ug/kg
TOXIC EFFECTS :
Gastrointestinal - nausea or vomiting
REFERENCE :
JCPYDR Journal of Clinical Pyschopharmacology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1981- Volume(issue)/page/year: 2,215,1982
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
10 mg/kg/5D-I
TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 1,406,1971
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
30 mg/kg
TOXIC EFFECTS :
Behavioral - coma Gastrointestinal - changes in structure or function of endocrine pancreas Gastrointestinal - decreased motility or constipation
REFERENCE :
JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 32,425,1994
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
3400 ug/kg/47M-I
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Cardiac - cardiomyopathy including infarction
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 3,698,1972
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
613 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973- Volume(issue)/page/year: 24,335,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
149 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973- Volume(issue)/page/year: 24,335,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
380 mg/kg
TOXIC EFFECTS :
Behavioral - wakefulness Behavioral - changes in motor activity (specific assay)
REFERENCE :
GWXXBX German Offenlegungsschrift Patent Document. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #2618152
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
150 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 21,448,1978
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
27 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
APSXAS Acta Pharmaceutica Suecica. (Apotekarsocieteten-Farmacevtiska Foereningen, Box 1136, S-111, 81 Stockholm, Sweden) V.1- 1964- Volume(issue)/page/year: 13,485,1976 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2857 ug/kg
SEX/DURATION :
male 4 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - impotence
REFERENCE :
CJPSDF Canadian Journal of Psychiatry. (Keith Health Care Communications, 289 Rutherford Rd. South, Suite 11, Brampton, ON L6W 3R9, Canada) Volume(issue)/page/year: 27,148,1982
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
50 mg/kg
SEX/DURATION :
female 38-47 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 24(1),42A,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
6850 mg/kg
SEX/DURATION :
female 1-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - other neonatal measures or effects
REFERENCE :
JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 29,479,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
420 mg/kg
SEX/DURATION :
lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical
REFERENCE :
PSCHDL Psychopharmacology (Berlin). (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.47- 1976- Volume(issue)/page/year: 56,93,1978
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
female 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - physical
REFERENCE :
PSCHDL Psychopharmacology (Berlin). (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.47- 1976- Volume(issue)/page/year: 56,93,1978
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
66 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
REFERENCE :
PSCHDL Psychopharmacology (Berlin). (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.47- 1976- Volume(issue)/page/year: 79,236,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
150 mg/kg
SEX/DURATION :
female 7-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
REFERENCE :
JNGSE8 Journal of Neural Transmission. General Section. (Springer-Verlag, Postfach 367, A-1011, Vienna, Austria) V.78- 1989- Volume(issue)/page/year: 90,113,1992

Safety Information

Hazard CodesXn: Harmful;
Risk PhrasesR20/21/22
Safety PhrasesS36
WGK Germany3
RTECSHN9055000
HS Code2933990090

Customs

HS Code2933990090
Summary2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Synonyms

3-Chloroimipramine
Chlorimipramine
3-Chloro-10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine
5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-
5H-Dibenz[b,f]azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-
MFCD00069234
Clomipramine
3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
5-(g-Dimethylaminopropyl)-3-chloroiminodibenzyl
3-Chloro-10,11-dihydro-5-(3-dimethylaminopropyl)-5H-dibenz[b,f]azepine
3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine
Hydiphen
Clomipramina
10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine
3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine
3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine
Monochlorimipramine
ANAFRANIL
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
chloripramine
EINECS 206-144-2
Chlomipramine
Anafranil base
CAS 932-17-2|N-Acetylpyrrolidone
CAS 886772-68-5|2-(4-Chloro-benzyl)-piperazine-1-carboxylic acid tert-butyl ester
Recommended......
TOP